FDA approves AbbVie’s VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cir…
FDA approves AbbVie’s VIEKIRA PAK for treatment of patients with GT1 HCV infection

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: